Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

The generalisability of r… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer

Artikel i vetenskaplig tidskrift
Författare J. de Boniface
J. Ahlgren
Y. Andersson
L. Bergkvist
J. Frisell
Dan Lundstedt
Roger Olofsson Bagge
L. Ryd?n
M. Sund
P. Christiansen
P. Christiansen
T. F. Tvedskov
B. V. Offersen
T. Reimer
T. K?hn
M. Kontos
O. Gentilini
R. Reitsamer
Publicerad i Breast Cancer Research and Treatment
Volym 180
Nummer/häfte 1
Sidor 167-176
ISSN 0167-6806
Publiceringsår 2020
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för onkologi
Wallenberg Centre for Molecular and Translational Medicine
Sidor 167-176
Språk en
Länkar dx.doi.org/10.1007/s10549-020-05537...
Ämnesord Breast cancer, Omission of axillary dissection, Clinical trial, Sentinel, lymph node biopsy, axillary dissection, phase-iii, radiotherapy, survival, surgery, biopsy, women, Oncology
Ämneskategorier Cancer och onkologi

Sammanfattning

Purpose None of the key randomised trials on the omission of axillary lymph node dissection (ALND) in sentinel lymph-positive breast cancer have reported external validity, even though results indicate selection bias. Our aim was to assess the external validity of the ongoing randomised SENOMAC trial by comparing characteristics of Swedish SENOMAC trial participants with non-included eligible patients registered in the Swedish National Breast Cancer Register (NKBC). Methods In the ongoing non-inferiority European SENOMAC trial, clinically node-negative cT1-T3 breast cancer patients with up to two sentinel lymph node macrometastases are randomised to undergo completion ALND or not. Both breast-conserving surgery and mastectomy are eligible interventions. Data from NKBC were extracted for the years 2016 and 2017, and patient and tumour characteristics compared with Swedish trial participants from the same years. Results Overall, 306 NKBC cases from non-participating and 847 NKBC cases from participating sites (excluding SENOMAC participants) were compared with 463 SENOMAC trial participants. Patients belonging to the middle age groups (p = 0.015), with smaller tumours (p = 0.013) treated by breast-conserving therapy (50.3 versus 47.1 versus 65.2%, p < 0.001) and less nodal tumour burden (only 1 macrometastasis in 78.8 versus 79.9 versus 87.3%, p = 0.001) were over-represented in the trial population. Time trends indicated, however, that differences may be mitigated over time. Conclusions This interim external validity analysis specifically addresses selection mechanisms during an ongoing trial, potentially increasing generalisability by the time full accrual is reached. Similar validity checks should be an integral part of prospective clinical trials. Trial registration: NCT 02240472, retrospective registration date September 14, 2015 after trial initiation on January 31, 2015

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?